Plasma Pyridoxal 5'-Phosphate Concentrations in Relation to Apo-Aminotransferase Levels in Normal, Uraemic, and Post-Myocardial Infarct Sera by Gressner, A. M. & Sittel, Daniela
Gressner and Sitte!: Plasma pyridoxal 5'-phosphate and apo-aminotransferases in health and disease 631
J. Clin. Chem. Clin. Biochem.
Vol. 23, 1985, pp. 631-636
Plasma Pyridoxal 5'-Phosphate Concentrations
in Relation to Apo-Aminotransferase Levels
in Normal, Uraemic, and Post-Myocardial Infarct Sera
By A. M. Gressner and Daniela Sittel
Abteilung für Klinische Chemie und Zentrallaboratorium, Philipps-Universität Marburg!Lahn
(Received January 14/May 28, 1985)
Summary: The concentrations of pyridoxal 5'-phosphate, and the holoenzyme activities and apoenzyme
contents of alanine aminotransferase and aspartate aminotransferase in plasma were determined sim-
ultaneously in healthy individuals, patients with renal insufficiency with and without chronic haemodialysis
and in patients with acute myocardial infarction. Plasma pyridoxal 5'-phosphate is significantly diminished
in uraemic patients and in post-myocardial infarct sera, healthy females have lower pyridoxal 5'-phosphate
levels (26.2 ± 9.0 nmol/1) than healthy males (41.0 ± 15.1 nmol/1). The Stimulation in vitro of the activities
of aspartate aminotransferase and alanine aminotransferase by addition of pyridoxal 5'-phosphate (0.1
mmol/1) was found to be independent of the endogenous coenzyme level. In sera of uraemic patients without
chronic haemodialysis an inverse statistic correlation between pyridoxal 5'-phosphate-induced Stimulation of
aspartate aminotransferase activity and the concentrations of urea (r = —0.696) and creatinine (r = —0.715)
was found. The respective correlations are much weaker for alanine aminotransferase. The apoenzyme
fraction was highest in post-myocardial infarct sera. Follow up of these patients did not reveal any
relationship between the fluctuations of pyridoxal 5'-phosphate levels and apoenzyme contents of both alanine
aminotransferase and aspartate aminotransferase. The results permit the conclusion that the degree of in
vitro Stimulation of aminotransferases by pyridoxal S'-phosphate can not be predicted from the endogenous
coenzyme level.
Pyridoxal-S'-phosphat-Konzentrationen im Plasma in Beziehung zu Apo-Aminotransferase-Gehalten in Sera
normaler Probanden sowie von Patienten mit Urämie und nach Herzinfarkt
Zusammenfassung: Die Konzentrationen von Pyridoxal-5'rphosphat im Plasma sowie Holoenzymaktivitäten
und Apoenzymgehalte von Alaninaminotransferase und Aspartataminotransferase im Serum wurden simultan
bei gesunden Probanden, Patienten mit Niereninsuffizienz mit und ohne chronischer Hämodialyse und bei
Patienten mit akutem Myokafdinfarkt bestimmt. Pyridoxalphosphat im Plasma ist bei Patienten mit Urämie
und nach Myokardinfarkt signifikant vermindert: gesunde weibliche Personen haben niedrigere Pyridoxal-
S'-phosphat-Konzentrationen (26,2 ± 9,0 nmol/1) als gesunde männliche Personen (41,0 ±15,1 nmol/1). Die
in vitro Stimulation der katalytischen Aktivitäten beider Aminotransferasen durch Präinkubation mit 0,1
mmol/1 (Endkonzentration) Pyridoxal-S'-phpsphat erwies sich als unabhängig von der endogenen Coenzym-
Konzentration. Mit Sera von urämischen Patienten ohne chronische Hämodialyse ergab sich eine negative
statistische Korrelation zwischen Pyridoxal-5'-phosphat-induzierter Stimulation der Aktivität von Aspartat-
aminotransferase und den Konzentrationen von Harnstoff (r = -0,696) und Kreatinin (r = -0,715). Die
diesbezüglichen Korrelationen sind für die Alaninaminotransferase wesentlich schwächer. Die Apoenzymfrak-
tionen waren in Postmyokardinfarkt-Sera am höchsten. Verlaufskontrolluntersuchungen bei Myokardinfarkt-
patienten zeigten keine Beziehung zwischen den Fluktuationen der Pyridoxal-5'-phosphat-Konzentration und
den Apoenzymgehalten beider Aminotransferasen. Aus den Ergebnissen wird geschlossen, daß der Grad der
iß vitro-Stimulation von beiden Aminotransferasen durch Pyridoxal-5'-phosphat nicht aus den endogenen
Coenzymkonzentrationen vorhergesagt werden kann.
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Introduction
The aminotransferases, aspartate aminotransferase
(EC 2.6.1.1) and alanine aminotransferase (EC
2.6.1.2), require the coenzyme, pyridoxal 5'-phos-
phate, for catalytic activity (1). The level of this active
metabolite of vitamin B6 in serum yaries considerably,
depending on nutritional Status and the type of de-
sease affecting a patient. Diminished plasma py-
ridoxal 5'-phosphate occurs, for example, in more
than 50% of chronic alcoholics (2), in about 70% of
patients with alcoholic liver cirrhosis (3), in patients
with renal insufficiency and nonuraemic kidney trans-
plant (4), and possibly also in otherwise healthy per-
sons (5). Consequently, it has been shown in several
studies that supplementation with pyridoxal 5'-phos-
phate of the assay for measuring the catalytic con-
centrations of both aminotransferases in serum re-
sults in enhanced activities, thus indicating the pre-
sence of appreciable amounts of apoamino-
transferases in the circulation (5 — 13). To avoid an
underestimation of in vitro activities of both ami-
notransferases by endogenous deficiency of pyridoxal
5'-phosphate a modification of the conventional as-
say (14) of both enzymes has been proposed by the
International Federation of Clinical Chemistry
(IFCC), in which the incubation mixture is sup-
plemented with 0.1 mmol/1 pyridoxal 5'-phosphate
(15, 16). During a preincubation period of 7 minutes
the apoenzyme fraction becomes saturated with the
coenzyme and is thereby fully reactivated (17).
Both human and experimental studies point to sig-
nificant differences in the degree of Stimulation of
both aminotransferases by added pyridoxal 5'-phos-
phate (18). The type of injury and not necessarily the
organ affected determines the degree of activation
(19). Patients with various diseases show different
increases in aspartate aminotransferase activity with
added coenzyme (20, 21), and the mitochondrial iso-
enzyme of aspartate aminotransferase behaves dif-
ferently from its cytosolic fraction (22). The quan-
titative differences in reactivation might be explained
by variable levels of circulating äpoamino-
transferases, by structural changes of the apoenzyme
fraction resulting in its partial inactivation, and/or
unresponsiveness to added pyridoxal S'-phosphate;
or additional, unidentified factors may also be invol-
ved. To gain more insight in the mechanisms un-
derlying the differences in reactivation, apoenzyme
levels of the aminotransferases should be directly
compared with actual concentrations of plasma py-
ridoxal 5'-phosphate. A recent study points to an
inverse relationship between the Stimulation of en-
zyme activity and pyridoxal S'-phosphate con-
centration -in plasma of healthy persons (23), but
similar studies in diseased individuals are lacking.
Therefore we determined the serum apoenzyme con-
tent of both aminotransferases in relation to the
plasma pyridoxal S'-phosphate concentration in
healthy individuals, in patients with proven pyridoxal
S'-phosphate deficiency and .ijjormal total ami-
notransferase activities (uraemic patients), and in
patients having elevated aspartate aminotransferase
activities (myocardial infarction). The results do not
reveal a relationship between coenzyme level in
plasma and apoaminotransferase content in serum.
Materials and Methods
Materials
Pyridoxal 5'-phosphate, apoenzyme of Lrtyfosine de-
carboxylase (1.1 U/mg) (EC 4.1.1.25), and tyramine · HC1 were
from Sigma Chem. Company, Munich, [3H]tyrosine (1998
GBq/mmol = 54 Ci/mmol) was from New England Nuclear,
Boston, USA.
Patients
Healthy persons (l l female and 11 male blood donors ranging
from 20 to 40 years) served äs a reference populatiön. Patients
with renal insufficiency (n = 46) were subdivided into those
undergoing haemodialysis (n = 26) and those without dialysis
(n = 20). Patients sufTering from acute myocardial infarction
(n = 12) were monitored with up to 6 consecutive meas-
urements within 14 days after hospital admission.
Assay of aspartate aminotransferase and alanine
aminotransferase v ·-
Venous blood was allowed to clot for 30 minutes, centrifuged
and the catalytic concentrations of both enzymes were meas-
ured either immediately or after storage of the sera for 24 h at
4°C. Both enzyme activities were determined at 25 °C ac-
cording to the fecommendations of the IFCC (15, 16) with
pyridoxal 5'-phosphate in the incubation mixture (final con-
centration 0.1 mmol/I, preincubation period 7.5 min) and
without pyridoxal 5'-phosphate under otherwise identieal con-
ditions, respectively. The reagents of the assays were from
Boehringer Mannheim GmbH, FRG; the method was adapted
to the Eppendorf ACP 5040 analyser. The accuracy of the
assays was checked with Precipath E, the precision from day
to day with a pool serum. The coefficient of Variation (CV)
was about 4% (mean activity 20 U/l) in the assays without
addition of pyridoxal 5'=phosphate. The CV of pyridoxal 5'-
phosphate-supplemented assays was lower at about 2%.
Holoenzyme concentration is defined äs the catalytic activity
in the presence of pyridoxal 5'-phosphate; the difference be-
tween the enzyme activities with and without supplementation
of pyridoxal 5'-phosphate reflects the apoenzyme level in serum;
activation is the percentage increase of activity after addition
of pyridoxal S'-phosphate.
Determination of pyridoxal S'-phosphate
About 5ml venous blood was collected in tubes containing
potassium EDTA äs an anticoagulant, promptly chilled in ice
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and centrifuged at 2 °C (1000g, 10 min) to obtain plasma. The
plasma was diluted l : 20 with potassium acetate (0.1 mol/1, pH
5.5) in which the concentration of pyridoxal 5'-phosphate was
determined in duplicate by a slightly modified radioenzymatic
procedure utilizing the Stimulation ofadded tyrosine apodecar-
boxylase by endogenous pyridoxal 5'-phosphate (24). Briefly,
200 μΐ of l : 20 diluted plasma .was mixed with 200 μΐ 0.1
mol/1 potassium acetate, pH 5.5 and 100 μΐ purified tyrosine
apodecarboxylase (10 g/l potassium acetate, pH 5.5) (25), incu-
bated for 30 min at 37 °C in the dark, cooled at 0 °C and
reincubated for l h at 37 °C after addition of 600 μΐ [3H]tyrosine
(74 GBq/mol) (24). The reaction is terminated by additions of
2 ml borate buffer (0.5 mol/1, pH 10.5), 0.8 g NaCl, and 6 ml
ethyl acetate. The mixture is vigorously extracted for 20 min,
centrifuged (10 min, 2000g) and 4ml of the upper layer is
counted for [3H]tyramine in a liquid scintillation counter.
The amount of [3H]tyramine generated is proportional to the
concentration of pyridoxal 5'-phosphate in the sample. The
results were calculated from a Standard curve ranging from
0.47 to 6.25 nmol/1 pyridoxal 5'-phosphate in the assay. In each
series the recovery of pyridoxal 5/-phosphate was checked and
found to be between 87 and 109%. The interassay coefficient













































Fig. l Frequency distribution of the concentration of
pyridoxal 5'-phosphate in plasma of healthy persons,
patients with myocardial infarction and renal in-
sufficiency with and without haemodialysis. Mean con-
centralions ± S. D. of each group are given. The
differences belween fcmalc and male healthy persons
and between total healthy persons and the various dis-
easc categorics are statistically significant (p ^ 0.01).
Statistical analysis
The statistical significance of differences was checked with
Pitmans permutation test (26); significance is indicated by
p ^ 0.05.
Results and Discussion
Concentrations of pyridoxal S'-phosphate in
normal and diseased individuals
The mean concentration ± S. D. of pyridoxal 5'-
phosphate in plasma s determined by the ra-
dioenzymatic method is 33.6 ± 14.3 nmol/1 which is
lower than that reported by others using different
procedures (for a summary see 1. c. (27)) but agrees
well with the data reported by Camp et al. (24),
applying an iderjtical nalytic principle, and others
(25, 28). Male healthy individuals have significantly
higher concentratioiis (41.0 ±15.1 nmol/1) than fe-
m le persons (26.2 ± 9.0 nmol/1) (fig. 1). The lower
concentration of pyridoxal S^phosphate in women
might be a consequence of the intake of oral con-
traceptive steroids (29). Patients suffering from renal
insufficiency exhibit reduced mean plasma pyridoxal
5'-jphosphate levels (15 nmol/1), which are similar in
patients reeeiving and not receiving haemodialysis,
thus confirming results of a previous report (4). An
inverse statistic correlatipn between the con-
centrations of rea or creatinine and plasma py-
ridoxal 5'-phpsphate is not evident (r < 0.340). Also
in patients with acute myocardial infarction a sig-
nificant reduction of the concentration of plasma
pyridoxal S'-phosphate is found, which is comparable
to that found in renal insufficiency (fig. 1).
Apoenzyme contents and Stimulat ion by py-
ridoxal 5'-phosphate of the catalyt ic ac-
tivities of serum aminotransferases
As detailed in table l the mean activities of aspartate
and alanine aminotransferase in healthy individuals
and renal insufficiency patients are similar, whereas,
s expected, in myocardial infarction a significant rise
of aspartate aminotransferase and, less pronounced,
of alanine aminotransferase is noticed. In healthy
males and females apoenzyme contents of aspartate
aminotransferase are 2.8 and 2.2 U/l, respectively,
amounting 14.2 and 12.0% of holoenzyme activity.
Apoenzyme activities and contents of alanine ami-
notransferase show a moderate, but statistically in-
significant elevation in female persons compared with
males. This difference might be a reflection of the
lower concentration of pyridoxal S'-phosphate in
plasma of females than in males reported above. If
this explanation holds true aspartate amino-
transferase activity in female persons exhibits either
a greater unresponsiveness to exogenous pyridoxal
5'-phosphate than alanine aminotransferase or the
Saturation levels with the coenzyme of both amino-
transferases in serum are different and not strictly
dependent on the concentration of pyridoxal 5'-phos-
phate in blood. This assumption is in line with pre-
vious findings, which show a much more pronounced
decrease of alanine aminotransferase than of as-
partate aminotransferase activities in liver and serum
of pyridoxine-deficient rats (18). Thus, the apparent
greater fraction of apoenzyme of alanine amino-
transferase in females could be due to a greater sen-
sitivity of this enzyme to a decrease of systemic py-
ridoxalphosphate.
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Tab. 1. Catalytic concentrations of aspartate aminotransferase and alanine aminotransferase in the absence and presence of
addcd pyridoxal 5'-phosphate (PLP, final concentration 0.1 mmol/1) in sera of healthy persons, patients with renal
insufficiency and patients with myocardial infarction. Apoenzyme is calculated from the diflference between holoenzyme
catalytic concentration (in the presence of added PLP) and catalytic activity concentration without added PLP and is
































































































































































Whereas this explanation might be valid for the dif-
ferences noticed between healthy males and females,
different mechanisms are effective in patients with
renal insufficiency. It is of great interest that py-
ridoxal 5'-phosphate is not able to stimulate aspartate
aminotransferase activity in uraemic patients un-
dergoing chronic haemodialysis (tab. 1). In fact, mean
activity is slightly inhibited by adding the coenzyme
and, by this criterion, an apoenzyme fraction of as-
partate aminotransferase is not detectable, although
these patients have a significantly reduced plasma
pyridoxal S'-phosphate concentration (flg. 1). Undi-
alysed uraemic patients have slightly higher apo-
enzyme levels than dialysed patients in spite of similar
pyridoxal 5'-phosphate levels. In both groups of
patients only a small apoenzyme fraction of alanine
aminotransferase, not different from that in normal
patients, was measured (tab. 1).
A statistic correlation between pyridoxal 5'-phos-
phate concentrations in plasma and apoamino-
transferase Contents is not evident in normal indivi-
duals (r = -0.102) or in uraemic patients, either
undialysed (r = -0.310) or dialysed (r = 0.095). It is
noteworthy that in uraemic patients without chronic
haemodialysis an inverse statistic cprrelation exists
between pyridoxal S'-phpsphate-induced Stimulation
of aspartate aminotransferase activity and the con-
centration of urea (r = —0.696) and creatinine (r =
-0.715) (fig. 2). With respect to the pyridoxal 5'-
phosphate-dependent Stimulation of alanine ami*
notransferase the correlation was much weaker, i. e.
r = -0.276 for urea and r = -0.330 för creatinine
(fig. 2). Patients sübjected to haemodialysis did not
exhibit a statistic correlation betweeri these para-
meters.
Taken together the results demonstrate that in
uraemic patients no statistically evident inter-
dependerice between the plasma level of pyridoxal 5'-
phosphate and the degree of pyridoxal SSphosphate-
induced activation of aspartate ammotransferase and
alanine aminotransferase exists. In fact, in sera of
patients with renal insufficiency, addition of py-
ridoxal S'-phosphate to the assay results in a small but
insignificant Inhibition of aspaftate aminotransferase
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Fig. 2. Statistical correlation between the concentrations of
urea, creatinine and Stimulation (activation) of the cata-
lytic concentrations of alanine aminotransferase and
aspartate aminotransferase by added pyridoxal S'-
phosphate in sera of patients with undialysed renal
insufllciency.
activity (not of alanine aminotransferase), although
these patients show a significant decrease of pyridoxal
S'-phosphate concentration in blood (fig. 1). The
mechanisms by which urea or creatinine (or other
Parameters accumulating in uraemic sera) influences
negatively the pyridoxal S'-phosphate-induced as-
partate aminotransferase activation needs further cla-
rification. Possibly, conformational changes of the
apoaminotransferases in highly uraemic sera might
hinder the binding of the coenzyme to the protein
moiety of the aminotransferase. Alternatively, py-
ridoxal S'-phosphate could be trapped and/or de-
graded (hydrolysed) by certain compounds that in-
crease in uraemic sera, and thereby be rendered un-
available to the apoenzyme.
Furthermore, differences in the isoenzyme pattern
of aspartate aminotransferase in serum under these
conditions might contribute to the effects described.
It has been reported that the mitochondrial fraction
of aspartate aminotransferase must be preincubated
with pyridoxal S'-phosphate longer than the cytosolic
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Fig. 3. Follow up of the catalytic concentrations of aspartate aminotransferase and alanine aminotransfcrase, their degrees of
Stimulation by pyridoxal S'-phosphate, and the concentrations of pyridoxal 5'-phosphate in sera and plasma of 6 patients
with acute myocardial infarction.
The time interval between the measurements is two to three days beginning with the first measurement after hospital
admission.
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Whereas the patients described above have activities
of transaminases within the reference ranges, similar
studies were performed in individuals afflicted with
acute myocardial infarction, and these patients pos-
sessed elevated levels of both transaminases. It is
demonstrated in table l that the apoenzyme content
of aspartate aminotransferase is significantly enhan-
ced in these patients, which is also true, but less
pronounced, for alanine aminotransferase. Trans-
aminase activity, pyridoxal 5'-phosphate-induced Sti-
mulation, and pyridoxal 5'-phosphate concentration
in plasma were followed up in patients with myocar-
dial infarction of which some examples are shown
in figure 3. The degree of pyridoxal 5'-phosphate-
induced Stimulation of aspartate aminotransferase
activity changes during the course of the disease in
loose parallelism to total aspartate aminotransferase
activity. The changes occur independently of the fluc-
tuations of pyridoxal 5'-phosphate in plasma. With
respect to alanine aminotransferase the degree of
Stimulation by pyridoxal 5'-phosphate and total acti-
vity vary independently of each other and of the
level of pyridoxal phosphate in blood (fig. 3). As an
example, alanine aminotransferase activation might
increase in spite of a pronouneed fall of total alanine
aminotransferase activity (right middle graph in flg.
3) or the degree of activation can change 3-fold with-
out accompanying changes in total alanine aminor
transferase activity (right, lower graph in fig. 3). Brie-
fly summarized, the results obtained from myocardial
infarction indicate for aspartate aminotransferase a
weak positive statistic correlation (r = 0.590) be-
tween total enzyme activity and apoenzyme content
or degree of pyridoxal phosphate-induced catalytic
activation. Alanine aminotransferase behaves diffe-
rently from aspartate aminotransferase because the
respective parameters of alanine aminotransferase
correlate only with r = 0.290.
After finishing this study a report was published,
which also failed to show an inverse relationship
between the concentrations of plasma pyridoxal 5'-
phosphate and the percentage Stimulation of the cata-
lytic activities of aspartate aminotransferase and ala-
nine aminotransferase, respectively (30)* Thüs, our
results confirm this lack of correlation.
References
1. Snell, E. E. & Dimari, S. J. (1970) Schiff base intermediate
in enzyme catalysis. In: The Enzymes // (Boyer, P. D., ed.)
Academic Press, New York and London, pp. 335 — 370.
2. Lumeng, L. & Li, T. K. (1974) J. Clin. Invest. 55, 693-704.
3. Rossouw, J. E., Labadarios, D. & Davis, M. (1978) S. Afr.
Med. J. 53, 436-438.
4. Lacour, B., Parry, C, Drücke, T, Touam, M., Kreis, H.,
Bailly, M. & Durand, D. (1983) Clin. Chim. Acta /27,
205-215.
5. Lustig, V. & Patten, R. (1976) Clin. Chim. Acta 69,
101-103.
6. Hambelt, A. (1966) Scahd. J. Clin. Lab. Invest. 18, Suppl.
92,181-188.
7. Ury, A. G. & Chassy, J. R. (1973) Clin. Chem. 19,
140-141.
8. Rosalki, S. B. & Bayoumi, R. A. (1975) Clin. Chim. Acta
59, 357-360.
9. Moss, D. W. (1976) Clin. Chim. Acta 67, 169-174.
10. Ratnaike, S. & Moss, D. W. (1977) Clin. Chim.Acta 74,
281-288.
11. Cheung, T. & Briggs, M. H. (1974) Clin. Chim. Acta 54,
127-129.
12. Garber, C. C., Feldbruegge, D. H. & Hoessel, M. (1981)
Clin. Chem. 27, 614-619.
13. H0rder, M. & Bowers, G. N. (1977) Clin. Chem. 23,
551-554.
14. Recommendations of the German Society for Clinical
Chemistry (1972) Z. Klin. Chem. Klin. Biochem. W,
281-291.
15. Bergmeyer, H. U., Horder, M. & Moss, D.W. (1977) J.
Clin. Chem. Clin. Biochem. 15, 719-720.
16. Bergmeyer, H. U. & Herder, M. (1980) J. Clin. Chem. Clin.
Biochem. 18, 521-534.
17. Herder, M., Moore, R.E. & Bowers, G.N. (1976) Clin.
Chem. 22, 1876-1883.
18. Ludwig, S. & Kaplowitz, N. (1980) Gastroenterology 79,
545-549.
19. De Waal, A., Le Roux, S., Potgieter, G. M-, Barnard,
H.C. & Schoombie, E. M:£P. (1980) Clin. Chim. Acta
/22, 395-401.
20. Garber, C. C., Hoessel, M., Wallendal, J. & Sarnat, G.
(1981) Clin. Chem. 27, 1035.
21. Bruns, D. E., Savory, J., Titheradge, A. C., Cross, R. E. &
Wills, M. R. (1981) Clin. Chem. 27, 156-159.
22. Kamei, S., Ohkubo, A. & Yamänaka, M. (1979) Clin.
Chim. Acta 96, 98-105.
23. Westerhuis, L. W. J. J. M. & Hafkenscheid, U. C. M. (1983)
Clin. Chem. 29, 789-792.
24. Camp, V. M., Chipponi, J. & Faraj,B. A. (1983) Clin.
Chern. 29, 642-644.
25. Hamfelt, A. (1967) Scand. J. Lab. Invest. 20, 1-10.
26. Sachs, L. (1972) Statistische Auswertungsmethoden 3. ed.
Springer, Berlin.
27. Coburn, S. P. & Mahuren, J. D. (1983) Anal. Biochem. /29,
310-317.
28. Chabner, B. & Livingston, D. (1970) Anal. Biochem. 34,
413-423.
29. Hontz, A. C., György, P., Baiin, H., Rose, C. S. & Shaw,
D. L. (1974) Am. J. Clin. Nutr. 27, 440.
30. Hafkenscheid, J. C. M., Rosier, J. G. M. C. & van Dijk,
C. M. C. E. (1984) Qin. Chim. Acta 144, 137-144.
Prof. Dr. A. M. Gressner l
Klinikum der Philipps-Universitat




J. Clin. Chem. Clin. Bioehem. / Vol. 23, 1985 / No. 10
